Latest From Tricida Inc.
Keeping Track: Ofev Snags SSc-ILD Indication, Accelerated Approval Reviews For Veverimer And Voxelotor, J&J Gets Its First Vaccine BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Not only did Tricida’s Phase III long-term extension study show safety for TRC101 in CKD metabolic acidosis patients, but also promise in renal health outcomes. Biomedtracker voiced caution on those findings, though, due to study limitations.
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.
- Therapeutic Areas
- Renal System
- Trilypsa Inc.
- North America
- Parent & Subsidiaries
- Tricida Inc.
- Senior Management
Gerrit Klaerner, PhD, Pres. & CEO
Geoffrey Parker, SVP, CFO
Claire Lockey, SVP, Chief Dev. Officer
Susannah Cantrell, PhD, SVP, Chief Commercial Officer
- Contact Info
Phone: (415) 429-7800
7000 Shoreline Ct.
South San Francisco, CA 94080
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.